Evidence map›Paper›PMID 41257178›Full record

ArticleERJ open research2025

Impact of oxygenation strategies on outcome in acute exacerbation of interstitial lung disease.

Robin Thévenin, André Gillibert, Nicolas Dognon, Mélanie Drucbert, Laurie Lagache, Mathieu Salaün, Antoine Cuvelier, Christophe Girault, Élise Artaud-Macari

Abstract read
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Robin ThéveninCHU Rouen, Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, Rouen, France.
André GillibertCHU Rouen, Department of Biostatistics, Rouen, France.
Nicolas DognonDepartment of Intensive Care Medicine, Critical Care Centre, CHU Lille, Lille, France.
Mélanie DrucbertRespiratory and Intensive Care, University Hospital Amiens, Amiens, France.
Laurie LagacheDepartment of Intensive Care Medicine, Le Havre Hospital, Montivilliers, France.
Mathieu SalaünCHU Rouen, Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, Rouen, France.
Antoine CuvelierCHU Rouen, Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, Rouen, France.ORCID https://orcid.org/0000-0003-0263-1845
Christophe GiraultCHU Rouen, Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, Rouen, France.
Élise Artaud-MacariCHU Rouen, Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, Rouen, France.ORCID https://orcid.org/0000-0001-7604-6839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: The benefit of noninvasive ventilation (NIV) in hypoxaemic acute respiratory failure is controversial and has never been studied in acute exacerbation of interstitial lung disease (AE-ILD). The potential protective effects of high-flow nasal cannula oxygen therapy (HFNC) also deserve to be evaluated in AE-ILD. Methods: We aimed to describe the respiratory management and compare outcome of adult patients with AE-ILD according to the initial oxygenation strategies, Results: A multicentre retrospective study has been conducted in intensive care units of four French tertiary hospitals between 1 January 2010 and 31 December 2021 with in-hospital mortality as primary outcome. Among 3962 screened patients, 163 were included: 118 with HFNC and 45 with NIV±HFNC. Analysis of changes in oxygenation strategy applied over the past decade have shown an increase in the use of HFNC, from 33.3% in 2010 to 79.2% in 2020. The adjusted in-hospital mortality rate was 55.2% (95% CI 36.0-74.4%) in the NIV±HFNC group Conclusion: The management of AE-ILD has progressively include the HFNC use during the past decade, despite the lack of evidence in the literature. Our study did not find any superiority of HFNC compared with NIV±HFNC in AE-ILD outcome but deserve further prospective trials with a larger population.

Identifiers

PMID41257178
PMCPMC12621123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.